Dongcheng Pharmaceutical (002675.SZ): Heparin sodium injection approved for listing with increased specifications

Zhitong Finance App News, Dongcheng Pharmaceutical (002675.SZ) announced that the company received a notice from its wholly-owned subsidiary Yantai Dongcheng North Pharmaceutical Co., Ltd. (“Dongcheng North”) to receive the “Drug Supplement Application Approval Notice” issued by the State Drug Administration, and that the new specification (0.2ml: 5000axAIU) for heparin sodium injection was approved for listing.

Heparin sodium injection is a low molecular weight heparin preparation. The main component is heparin sodium, which has antithrombotic and anticoagulant effects. The main indication is the treatment of acute deep venous thrombosis. Prevent blood clots in the extracorporeal circulation system during hemodialysis and blood filtration in people with acute renal failure or chronic renal insufficiency. Treat unstable coronary artery disease, such as unstable angina pectoris and non-Q-wave myocardial infarction. Prevent thrombus formation associated with surgery.